Featured
Outdated Cost-Effectiveness Analysis (CEA) Methodology Abroad Can Delay Access to Life-Saving Medicines for Patients in the U.S. and Globally and Disincentivize Future Innovation
86 percent of respondents shared concerns that state-run Prescription Drug Affordability Boards (PDABs) will limit treatment options; 51 percent said medicines prescribed by their doctor were denied by their insurer
“If a doctor prescribes a treatment and the insurer authorizes it, the copay should be affordable.”